Bioprogress is a stock I have been in and out of quite a few times since it floated in May but not much mention here on the Investors' Room. Does anyone else follow this stock. I see it is up 1.5p today and a few good buyers seem to have appeared.

Anyone interested in BPRG should view these videos - courtesy of Paul Bye on ADVFN.

They really are quite interesting - and it does appear that BPRG are starting to get their act together. I have traded these over the past few months on their ups and downs - but think that now may be the time to consider re investing for the longer term as I think they are on the up.

Use the links below and scroll to the bottom of the screen and click on the box that says Click here to play animation Quicktime required

http://www.pixelwork.com/workDetail.cfm?projectID=198&catID=2

http://www.pixelwork.com/workDetail.cfm?projectID=197&catID=2


You will need quicktime (doh) http://www.apple.com/quicktime/download/win.html

and Id recommend using Broadband / LAN as dial up would take too long to load.

Baza

These definitely appear to be in the ascendancy

BPRG looks as though it has had a rough couple of days (ever since I decided to buy back in) - but looks as though it is on the turn now. - well at least - I for one hope so

Baza

I think this share from its TA is at last on a definite up channel (with a trend P/A rate 8-) of----------------------( not telling )) DYOH

Thanks Fred - I couldn't work out what all those yachts were doing - one or two seemd to have capsized - but the big one is in the lead

Baza

Blimey, I must sound a real fool...thought they were sharks (and there's a few out there!!)....

Good times ahead, at last.

Not been in BPRG for long - but hope all those that have been in long term start to recover their losses as the SP starts to climb on good news

thanks bhunt.............its better than a lot of abusive people on here and on advfn who thrive on people losing money.

I think thats very sad

Moving up nicely again today!

BioProgress PLC
22 November 2005

SCHEDULE 10

NOTIFICATION OF MAJOR INTERESTS IN SHARES


1. Name of company

BioProgress plc

2. Name of shareholder having a major interest
FMR Corporation and its direct and indirect subsidiaries; and
Fidelity International Limited and its direct and indirect subsidiaries

3. Please state whether notification indicates that it is in respect of
holding of the shareholder named in 2 above or in respect of a non-
beneficial interest or in the case of an individual holder if it is a
holding of that person's spouse or children under the age of 18.

As above

4. Name of the registered holder(s) and, if more than one holder, the
number of shares held by each of them
797,233 Brown Brothers Harriman Ltd Lux
4,376,349 Mellon Bank N.A.

5. Number of shares/amount of stock acquired

1,394,681 ordinary shares

6. Percentage of issued class

Not disclosed

7. Number of shares/amount of stock disposed

Not disclosed

8. Percentage of issued class

Not disclosed

9. Class of security

Ordinary shares of 1p each

10. Date of transaction

Not disclosed

11. Date company informed

21st November 2005

12. Total holding following this notification

5,173,582

13. Total percentage holding of issued class following this notification

4.18%

14. Any additional information

15. Name of contact and telephone number for queries

Daniel Farrow - 01354 655674

16. Name and signature of authorised company official responsible for making
this notification.

Daniel Farrow, Finance Director

Date of notification: 22nd November 2005

I think it is about to breakout

It might hover around 43/44 - but there is a very positive feel about this share now.

Would not surprise me to see 50 by end of week.

There - thats put the kiss of death on it

Don't tell Dil.


Going like the clappers!!!!!!!


Double post

lol Fred but I've only ever called it as I see it


Dil - 02 Nov 2005 20:52 - 2153 of 2173
Must say the chart looks healthier .

48/50

Its broken that resistance barrier of 47 - I think this is now fully into recovery mode _ certainly am having bought a few for a punt at 29 - so quite happy with this. Shame about all the slagging off going on over on ADVFN - just not necessary

Yep , still looks positive.

Still looking good


Interview with Richard Trevillion

Richard Trevillion has conducted a 10-minute interview with CEOcast and has been approved by Dan for release.

http://www.ceocast.com/company.cfm?cid=19351



For the record, here is a transcript of this Ceocast interview 22 November 2005 (I have edited it for grammar etc to make it read better):


Michael: Good-day, this is Michael Wax with Ceocast. Im here today with Richard Travillion, Richard is Chief Executive Officer of BioProgress plc. A company that trades on the NASDAQ, under the symbol BPRG, one that is a European based company. Thanks for joining Ceocast, Richard.

Richard: My pleasure.

Michael: Perhaps you could begin with an overview of the company, and then what I thought we would do is get into the business in greater detail and talk about some of your trading results.

Richard: OK, will do. As an overview, BioProgress was established to exploit the uses of non-gelatin film for a variety of industrial uses. Over time, the company has focused on the exploitation of the non-gelatin film, both in ingestible form and non-ingestible form. And in particular, in using film as a means of encapsulating a variety of substances and over time focusing on the health-care market in particular the pharmaceutical market and the medical-device market. Currently we have a range of grounded solutions across those two market areas. In the pharmaceutical market we provide alternatives to gelatin, sugar-coating, and other industry normal means of encapsulating pharmaceutical orally delivered products. Replacing the traditional powder-coating methods and encapsulation, providing alternative to tablet-coating, [and] providing an alternative to liquid encapsulation. And we also have the ability to encapsulate in the film itself on a film strip a variety of active substances as well as bits of mineral substances.

On the non-ingestible side, as I described, the medical-device side, we have a range of technologies used for encapsulating a variety of medical-waste. And we currently have a number of partnerships, both across those industry areas, going from the medical-device to the pharma. On medical-devices we have a partnership with a division of Bristol-Myers-Squib called Convatec. And we are working with them using our non-ingestible technology in the field of ostomy.

We also have a partnership with FMC BioPolymer, for our encapsulation of powder, pharmaceutical powder encapsulation. And we have a number of relationships with our film-strip technology.

Michael: You recently developed, or delivered your first NRobe machine for powder encapsulation. How big a market opportunity is this?

Richard: The market for oral-ingested pharmaceutical products is vast, and there are various definitions of that market, ranging upwards of $500 billion. The powder element of that is difficult to quantify, because most pharmaceutical products, the actives can be constituted either in a powder, liquid or hard-tablet fashion. So its particularly complicated to provide the market in such a way. But what I think it is possible to say is that it is a meaningful portion of that market size. Clearly most ingestible pharmaceutical products have presentations in the form of powder, so we are certainly looking at a very large and growing market segment.

Michael: As you look at the Tabwrap machine, whats the opportunity here, and how far off from market do you think you are?

Richard: The Tabwrap machine is the brand we use to.. for.. is actually the replacing the traditional forms of hard-tablet coating. NRobe, as I mentioned before, covers the powder-coating. Once again, breaking the market down into tablets verses powder, verses liquid, verses other forms, is fraught with difficulties. But we showcased our prototype Tabwrap machine at a recent global event housed in Madrid a few weeks ago. The reception we got from that was extremely encouraging, and we are in the process of, like the rest of our technologies, in aggressively commercializing this as an alternative to current methods.

Michael: Given the opportunities with partners, what types of partners have you focused on?

Richard: Traditionally the company has attracted a number of very large partners. Addressing that question looking at both our areas, that being pharmaceuticals i.e. the ingestible and the medical-devices. Both industries, although dominated by some very large players, are still fairly fragmented. And also both industries are supported by other industries, for example the contract manufacturing industry, who also represent potential partners to the business. So the answer, I think to the question is we are in discussions with a number of organizations across the size[entire?] spectrum. Both principle players within those particular segments but also players that are supportive or support industries of those players.

Michael: What kind of catalysts will there be, perhaps for sales growth?

Richard: Well, in terms of the sales, we have currently two revenue streams within the business. Our core historic platform technologies, the model is one of licensing and royalties, whereby we license out the rights to use the technologies thereby not encumbering ourselves with a very expensive infrastructure. And thats relevant to all the technologies I have previously described bar the in-the-mouth, or using the film as a delivery technology in its own right.

Focusing on that for a moment, which in fact was brought us into the business through an acquisition last year. The in-the-mouth instantly dissolving film, we have a division that operates out of Florida in the US, which as you very rightly said, the first part of the year had very sluggish sales. Youll no doubt have noticed from the web site and the various announcements we have made to the market, that the company has gone through a fairly extensive restructuring exercise of the course of the past 6 to 9 months. And that has been a very lengthy but whats becoming a very successful exercise, and we are expecting there to be a very distinct improvement following that restructuring.

Michael: As you now look at the opportunities going forward, where do acquisitions or in-licensing of products fit in?

Richard: As a business we will always look at opportunities that fits within both our core constancies and also fit within both our.. that are allied to our business model. In terms of in-licensing, I think once again, the same applies. The industry in which we operate is one that is in constant change, constant evolution, and constant development, and opportunities arise on a very regular basis. And I think any company of our size and our stage in the market, will be reviewing those opportunities as they add value and create shareholder value through the synergies with the core technologies of the business over time.

Michael: What should investors now look for in the coming quarters in the terms of key developments?

Richard: The key developments, Ive hinted at one, in that, as I mentioned before, weve undergone a very extensive restructuring that was required by the company significantly underperforming and having suffered some major issues in the past. And Ive already mentioned in this interview and in previous correspondence with the market, that were expecting to elaborate on the results of that restructuring at the backend of this year.

Michael; [Wraps up].

Baza

This is getting quite exciting

Now 53/54

Yes very exciting indeed!

really. really exciting!

lol